Pipeline

Overview 2017-12-14T04:44:20+00:00

Therapeutic Area

Drug/ Target

Indication
Preclinical
Phase I
Phase II
Phase III

Anticipated Milestones

Anticipated Milestones

Complete enrollment mid 2018

Patient enrollment ongoing
 

Initiate registration supporting trial in 2018

Anticipated Milestones

Initiate studies for Primary FSGS: non-nephrotic and nephrotic syndrome

Vifor has future option

Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

Progress in TH17 Disease
 

Drug: Indication (Target)
Pre
PI
PII
PIII
Anticipated Milestones

Initiate combination checkpoint inhibitor trial in 2018